TFC Financial Management, Inc.
Position in UNCY — Unicycive Therapeutics, Inc.
CIK 1827844
BOSTON, MA
Position in UNCY
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$1,407
-$567 QoQ
Shares Held
300
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#72
of 80 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in UNCY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TFC Financial Management, Inc. holds $462,229 across 45 Biotechnology names. UNCY ranks #23 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
316 | $156,966 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
89 | $55,495 | |
| 3 | TNGX |
Tango Therapeutics, Inc.
|
1,650 | $51,579 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
620 | $33,814 | |
| 5 | REPL |
Replimune Group, Inc.
|
2,691 | $29,789 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
72 | $21,674 | |
| 7 | MRNA |
Moderna, Inc.
|
264 | $18,487 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
211 | $16,514 |
All Filings in UNCY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,407 | 300 | Shares | Sole | 2026-07-23 | |
| 2026-03-31 | $1,974 | 300 | Shares | Sole | 2026-04-23 | |
| 2025-12-31 | $1,731 | 300 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $1,308 | 300 | Shares | Sole | 2025-10-24 | |
| No filing history on record for this holder in this stock. | ||||||